Ryan B. Corcoran

22.2k total citations · 5 hit papers
132 papers, 8.1k citations indexed

About

Ryan B. Corcoran is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ryan B. Corcoran has authored 132 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 55 papers in Molecular Biology and 45 papers in Cancer Research. Recurrent topics in Ryan B. Corcoran's work include Colorectal Cancer Treatments and Studies (45 papers), Cancer Genomics and Diagnostics (44 papers) and Melanoma and MAPK Pathways (25 papers). Ryan B. Corcoran is often cited by papers focused on Colorectal Cancer Treatments and Studies (45 papers), Cancer Genomics and Diagnostics (44 papers) and Melanoma and MAPK Pathways (25 papers). Ryan B. Corcoran collaborates with scholars based in United States, Italy and Japan. Ryan B. Corcoran's co-authors include Jeffrey A. Engelman, Bruce A. Chabner, Kevin D. Courtney, Matthew P. Scott, Jeffrey Settleman, Rona Yaeger, Meagan B. Ryan, Arnold J. Levine, Diane Pennica and Lifeng Xu and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Ryan B. Corcoran

125 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PI3K Pathway As Drug Target in Human Cancer

2010 991 citations Ryan B. Corcoran, Jeffrey A. Engelman et al. profile →
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

2012 767 citations Ryan B. Corcoran, Hiromichi Ebi et al. Cancer Discovery profile →
Application of Cell-free DNA Analysis to Cancer Treatment

2018 648 citations Ryan B. Corcoran, Bruce A. Chabner profile →
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

2015 382 citations Ryan B. Corcoran, Chloé E. Atreya et al. profile →
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

2021 302 citations Noritaka Tanaka, W. Marston Linehan et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryan B. Corcoran United States	36	4.9k	3.7k	2.1k	1.7k	1.6k	132	8.1k
Rodrigo Dienstmann Spain	37	3.2k 0.7×	3.4k 0.9×	2.2k 1.0×	1.7k 1.0×	1.4k 0.9×	179	7.0k
Mark Basik Canada	41	3.5k 0.7×	2.8k 0.8×	2.9k 1.4×	1.0k 0.6×	1.3k 0.8×	142	7.2k
Giancarlo Troncone Italy	53	4.0k 0.8×	3.3k 0.9×	3.0k 1.5×	2.5k 1.5×	1.4k 0.9×	356	9.7k
Wells A. Messersmith United States	52	4.3k 0.9×	5.3k 1.4×	1.7k 0.8×	1.8k 1.1×	1.2k 0.8×	298	9.5k
Dominic T. Moore United States	42	2.7k 0.6×	3.5k 0.9×	2.8k 1.4×	2.1k 1.2×	1.2k 0.7×	128	8.0k
Jennifer J. Wheler United States	42	3.2k 0.7×	2.6k 0.7×	2.1k 1.0×	1.8k 1.1×	919 0.6×	199	6.7k
Gerald S. Falchook United States	50	5.2k 1.1×	5.4k 1.4×	2.5k 1.2×	2.6k 1.6×	1.5k 1.0×	390	10.6k
Bijoyesh Mookerjee United States	30	4.1k 0.8×	3.7k 1.0×	2.3k 1.1×	2.2k 1.4×	781 0.5×	85	7.4k
Antonella De Luca Italy	38	3.6k 0.7×	3.4k 0.9×	1.4k 0.7×	1.7k 1.0×	619 0.4×	102	6.8k
Fiamma Buttitta Italy	45	3.6k 0.7×	3.5k 0.9×	2.4k 1.2×	2.9k 1.8×	702 0.4×	102	7.1k

Countries citing papers authored by Ryan B. Corcoran

Since Specialization

Citations

This map shows the geographic impact of Ryan B. Corcoran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan B. Corcoran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan B. Corcoran more than expected).

Fields of papers citing papers by Ryan B. Corcoran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan B. Corcoran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan B. Corcoran. The network helps show where Ryan B. Corcoran may publish in the future.

Co-authorship network of co-authors of Ryan B. Corcoran

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan B. Corcoran. A scholar is included among the top collaborators of Ryan B. Corcoran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan B. Corcoran. Ryan B. Corcoran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parikh, Aparna R., Thereasa A. Rich, Kristin S. Price, et al.. (2024). Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Clinical Cancer Research. 30(14). 2964–2973. 10 indexed citations

Rubinson, Douglas A., Noritaka Tanaka, Ferran Fece de la Cruz, et al.. (2024). Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers. Cancer Discovery. 14(5). 727–736. 23 indexed citations

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations

Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228. 1 indexed citations

Ellis, Haley, Giulia Siravegna, Alexa Michel, et al.. (2023). Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clinical Cancer Research. 30(1). 198–208. 38 indexed citations

Ryan, Meagan B., Alexey V. Sorokin, Edmond Wong, et al.. (2022). KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Reports. 39(12). 110993–110993. 76 indexed citations

Tanaka, Noritaka, W. Marston Linehan, Chendi Li, et al.. (2021). Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation. Cancer Discovery. 11(8). 1913–1922. 302 indexed citations breakdown →

Best, Till D., Eric Roeland, Nora Horick, et al.. (2021). Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. The Oncologist. 26(6). e963–e970. 18 indexed citations

Jalili, Pégah, Adam Langenbucher, Karmen Aguirre, et al.. (2020). Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nature Communications. 11(1). 2971–2971. 70 indexed citations

10.

Juric, Dejan, Andrzej Niemierko, Laura M. Spring, et al.. (2020). Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology. 1246–1262. 15 indexed citations

11.

Kamran, Sophia C., Jochen K. Lennerz, Claire A. Margolis, et al.. (2019). Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research. 25(18). 5561–5571. 62 indexed citations

12.

Yaeger, Rona, Daisuke Kotani, Sebastián Mondaca, et al.. (2019). Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer. Clinical Cancer Research. 25(23). 7089–7097. 85 indexed citations

13.

Strickler, John H., Jonathan M. Loree, Leanne G. Ahronian, et al.. (2017). Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery. 8(2). 164–173. 196 indexed citations

14.

Kwak, Eunice L., Leanne G. Ahronian, Giulia Siravegna, et al.. (2015). Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET -Amplified Esophagogastric Cancer. Cancer Discovery. 5(12). 1271–1281. 138 indexed citations

15.

Corcoran, Ryan B.. (2015). New therapeutic strategies for BRAF mutant colorectal cancers.. Europe PMC (PubMed Central). 6(6). 650–9. 27 indexed citations

16.

Alagesan, Brinda, Gianmarco Contino, Alexander R. Guimarães, et al.. (2014). Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research. 21(2). 396–404. 103 indexed citations

17.

Corcoran, Ryan B., S. Michael Rothenberg, Aaron N. Hata, et al.. (2013). TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine. 5(196). 196ra98–196ra98. 110 indexed citations

18.

Corcoran, Ryan B., Hiromichi Ebi, Alexa B. Turke, et al.. (2012). EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery. 2(3). 227–235. 767 indexed citations breakdown →

19.

Corcoran, Ryan B., Gianmarco Contino, Vikram Deshpande, et al.. (2011). STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis. Cancer Research. 71(14). 5020–5029. 334 indexed citations

20.

Corcoran, Ryan B. & Matthew P. Scott. (2006). Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proceedings of the National Academy of Sciences. 103(22). 8408–8413. 251 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact